Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) has demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age and 68% efficacy in autologous hematopoietic stem cell transplant recipients ≥18 years of age. We report the immunogenicity and safety of RZV administered to...

Descripción completa

Detalles Bibliográficos
Autores principales: Vink, Peter, Delgado Mingorance, Ignacio, Maximiano Alonso, Constanza, Rubio‐Viqueira, Belen, Jung, Kyung Hae, Rodriguez Moreno, Juan Francisco, Grande, Enrique, Marrupe Gonzalez, David, Lowndes, Sarah, Puente, Javier, Kristeleit, Hartmut, Farrugia, David, McNeil, Shelly A., Campora, Laura, Di Paolo, Emmanuel, El Idrissi, Mohamed, Godeaux, Olivier, López‐Fauqued, Marta, Salaun, Bruno, Heineman, Thomas C., Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766894/
https://www.ncbi.nlm.nih.gov/pubmed/30707761
http://dx.doi.org/10.1002/cncr.31909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766894/
https://www.ncbi.nlm.nih.gov/pubmed/30707761
http://dx.doi.org/10.1002/cncr.31909

Ejemplares similares